在日本,使用BNT162b2进行COVID-19强剂疫苗接种的成本效益分析
Mitsuhiro Nagano1, Kazumasa Kamei1, Hiroyuki Matsuda2
1Health and Value, Pfizer Japan Inc., Tokyo, Japan.
Expert review of vaccines
|February 27, 2024
概括
在日本使用BNT162b2进行的COVID-19复发疫苗是具有成本效益和有益的. 年度和半年战略都改善了老年人和高风险人群在Omicron浪潮期间的公共卫生结果.
科学领域:
- 公共卫生 公共卫生
- 卫生经济学 卫生经济学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 在日本的Omicron主导时期 (2022年初) 评估COVID-19强剂疫苗接种 (BNT162b2) 的影响.
- 评估疫苗接种策略对公众健康和经济的影响.
研究的目的:
- 评估每年或两年一次用BNT162b2.2.进行的COVID-19复发疫苗接种的成本效益.
- 为了比较针对日本特定年龄和风险群体的增强剂策略与不接种疫苗.
主要方法:
- 使用组合队列马尔科夫决策树模型.
- 从社会角度考虑,包括敏感性和场景分析.
- 专注于65岁及以上的个人,以及60-64岁的高风险个人.
主要成果:
- 从社会角度来看,每年和每两年一次的补充疫苗接种策略被发现是占主导地位的.
- 增量成本效益比率 (ICER) 在年度和半年战略中都低于日本的500万日元/QALY门.
- 结果在各种年龄组,风险概况和敏感性分析中保持一致.
结论:
- 在日本,用BNT162b2进行强剂疫苗接种是占主导地位和有益的公共卫生策略.
- 这些发现支持实施强剂疫苗接种计划,以减轻COVID-19的影响.
更多相关视频
09:37Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
1.9K
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
2.2K
相关概念视频
Vaccinations
44.5K
Overview
44.5K
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
Bias in Epidemiological Studies
268
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
268
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Odds Ratio
138
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
138
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
